Global Sales for New Formulations Range Between $65 Million and $8 Billion Annually Among Surveyed Companies
Despite Significant Costs, Forty-Five Percent of Surveyed Companies Use New Formulations as a Line Extension Strategy, According to Cutting Edge Information
/EINPresswire.com/ -- RESEARCH TRIANGLE PARK, NC--(Marketwired - February 16, 2016) - Although deciding on a new formulation as a way to extend a product line requires significant investment, this lifecycle management (LCM) strategy can also yield significant returns. Global sales for new formulations range from $65 million to $8 billion among surveyed companies, according to primary intelligence provider Cutting Edge Information.
Forty-five percent of surveyed companies in Pharmaceutical Lifecycle Management: Expand and Extend Portfolio Value with a Well-Integrated LCM Strategy leverage new formulations as a line extension strategy, making it the second most popular lifecycle tactic among surveyed teams. A new formulation is costly and time-consuming, as additional clinical trials must be performed to prove the safety and efficacy of the new product. However, new formulation tactics have proven highly effective.
"A team with a successful brand can gain a lot by investing in a new formulation," said Natalie DeMasi, senior analyst at Cutting Edge Information. "With global sales for new formulations among surveyed companies ranging from $65 million to $8 billion annually, life sciences groups stand to gain a lot by considering this LCM strategy."
Pharmaceutical Lifecycle Management: Expand and Extend Portfolio Value with a Well-Integrated LCM Strategy, available at http://cuttingedgeinfo.com/research/portfolio-management/lcm-strategy/, includes detailed metrics and case studies for 14 different lifecycle management strategies, such as new formulations, new dosages, combination products and next-generation products. Metrics include average implementation costs, average return-on-investment, timelines for planning and executing each tactic, as well as primary goals for implementing each strategy.
LCM teams can use this report to understand how top life science companies:
- Build a robust LCM strategy by combining market enhancement and line extension tactics
- Create a dedicated LCM team and cross-functional committee to develop the most effective lifecycle management plans
- Implement strong leadership to ensure a successful LCM strategy
- Generate excitement with cost-effective publications strategies
- Invest in next-generation drug development to yield large returns
To learn more about Cutting Edge Information and its research report offerings, please visit http://cuttingedgeinfo.com/.
Image Available: http://www.marketwire.com/library/MwGo/2016/2/15/11G082871/Images/Prevalence_of_LCM_Strategies-c4c986d5dbfc9b01b45ffeb768303ac8.jpg
CONTACT
Rachel Shockley
Marketing Team Lead
rachel_shockley@cuttingedgeinfo.com
919-433-0211
Forty-five percent of surveyed companies in Pharmaceutical Lifecycle Management: Expand and Extend Portfolio Value with a Well-Integrated LCM Strategy leverage new formulations as a line extension strategy, making it the second most popular lifecycle tactic among surveyed teams. A new formulation is costly and time-consuming, as additional clinical trials must be performed to prove the safety and efficacy of the new product. However, new formulation tactics have proven highly effective.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
